Trials / Completed
CompletedNCT01375036
Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients
A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates From Patients With Cystic Fibrosis in the United States [AIR-CF5]
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 510 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, longitudinal, 5-year study that will enroll participants from the existing Cystic Fibrosis Foundation (CFF) patient registry. Each enrolled participant will provide samples for microbiological evaluation, obtained upon enrollment and then once per year thereafter for 5 years.
Conditions
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2011-06-17
- Last updated
- 2017-01-11
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01375036. Inclusion in this directory is not an endorsement.